Could a nausea drug help fight COVID-19? early trial cut short
NCT ID NCT04470622
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether adding aprepitant, a drug usually used for nausea, to standard care could help hospitalized COVID-19 patients recover faster. The study planned to enroll adults recently admitted to the hospital with COVID-19 and signs of lung involvement. However, the trial was terminated early after enrolling only 27 participants, so the results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aprepitant injectable emulsion
What this could lead to
If it works, this could point toward a new treatment to help hospitalized COVID-19 patients recover faster and avoid severe outcomes.
What could go wrong
This was a small, early-phase trial that was terminated before completion, so results are limited and may not be reliable. Aprepitant is not a proven treatment for COVID-19.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Helen Keller Hospital
Sheffield, Alabama, 35660, United States
-
University of California, Irvine Medical Center
Orange, California, 92868, United States
-
Yale University School of Medicine
New Haven, Connecticut, 06510, United States